|
[1]
|
He X, Xing H, Ruan YH, Hong KX, Cheng CL, Hu YY, et al. A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLoS One 2012;7(10):e47289. http://dx.doi.org/10.1371/journal.pone.0047289CrossRef
|
|
[2]
|
Han XX, An MH, Zhang WQ, Cai WP, Chen X, Takebe Y, et al. Genome sequences of a novel HIV-1 circulating recombinant form, CRF55_01B, identified in China. Genome Announc 2013;1(1):e00050 − 12. http://dx.doi.org/10.1128/genomeA.00050-12CrossRef
|
|
[3]
|
Liang BY, Wei QY, Yang Y, Yang Y, Liu J, Chu JM, et al. Identification of a novel HIV-1 CRF55_01B/B recombinant isolate in Guangxi, China. AIDS Res Hum Retroviruses 2020;36(5):434 − 9. http://dx.doi.org/10.1089/aid.2019.0222CrossRef
|
|
[4]
|
Chinese Center for Disease Control and Prevention. Notice of the General Office of the National Health and Family Planning Commission on adjusting the standard of free antiviral treatment for AIDS. 2016. http://www.chinaaids.cn/zlgh/hdjz6/201606/t20160615_131433.htm. [2016-6-15]. (In Chinese). http://www.chinaaids.cn/zlgh/hdjz6/201606/t20160615_131433.htm |
|
[5]
|
Benson C, Wang X, Dunn KJ, Li N, Mesana L, Lai J, et al. Antiretroviral adherence, drug resistance, and the impact of social determinants of health in HIV-1 patients in the US. AIDS Behav 2020;24(12):3562 − 73. http://dx.doi.org/10.1007/s10461-020-02937-8CrossRef
|
|
[6]
|
Kang RH, Liang SJ, Ma YL, Liang S, Xiao L, Zhang XH, et al. Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017. Infect Dis Poverty 2020;9(1):54. http://dx.doi.org/10.1186/s40249-020-00668-5CrossRef
|
|
[7]
|
World Health Organization. HIV drug resistance surveillance guidance, 2015 update. 2016. https://apps.who.int/iris/handle/10665/204471. [2020-2-5].https://apps.who.int/iris/handle/10665/204471 |
|
[8]
|
Gan MZ, Zheng S, Hao JJ, Ruan YH, Liao LJ, Shao YM, et al. The prevalence of CRF55_01B among HIV-1 strain and its connection with traffic development in China. Emerg Microbes Infect 2021;10(1):256 − 65. http://dx.doi.org/10.1080/22221751.2021.1884004CrossRef
|
|
[9]
|
Ye JR, Hao MQ, Xing H, Zhang FJ, Wu H, Lv W, et al. Transmitted HIV drug resistance among individuals with newly diagnosed HIV infection: a multicenter observational study. AIDS 2020;34(4):609 − 19. http://dx.doi.org/10.1097/QAD.0000000000002468CrossRef
|
|
[10]
|
McClung RP, Oster AM, Ocfemia MCB, Saduvala N, Heneine W, Johnson JA, et al. Transmitted drug resistance among HIV-1 diagnoses in the United States, 2014–2018. Clin Infect Dis, 2021ciab583. http://dx.doi.org/10.1093/cid/ciab583.CrossRef
|
|
[11]
|
Liu YJ, Li HP, Wang XL, Han JW, Jia L, Li TY, et al. Natural presence of V179E and rising prevalence of E138G in HIV-1 reverse transcriptase in CRF55_01B viruses. Infect Genet Evol 2020;77:104098. http://dx.doi.org/10.1016/j.meegid.2019.104098CrossRef
|
|
[12]
|
Zhang D, Zheng CL, Li HP, Li H, Liu YJ, Wang XL, et al. Molecular surveillance of HIV-1 newly diagnosed infections in Shenzhen, China from 2011 to 2018. J Infect 2021;83(1):76 − 83. http://dx.doi.org/10.1016/j.jinf.2021.04.021CrossRef
|
|
[13]
|
Dong AB, Liu L, Xiao L, Liang S, Li K, Hu J, et al. First detection of a circulating recombinant form of HIV-1 CRF01_AE/08_BC (CRF105_0108) with drug-resistant mutations in Sichuan, China. AIDS Res Hum Retroviruses 2020;36(7):625 − 30. http://dx.doi.org/10.1089/AID.2020.0034CrossRef
|
|
[14]
|
Wei L, Li H, Lv X, Zheng CL, Li GL, Yang ZR, et al. Impact of HIV-1 CRF55_01B infection on the evolution of CD4 count and plasma HIV RNA load in men who have sex with men prior to antiretroviral therapy. Retrovirology 2021;18(1):22. http://dx.doi.org/10.1186/s12977-021-00567-zCrossRef
|